Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Key Stats

• Today's Range: $17.54 to $17.54
• 50-Day Range: $9.42 to $17.54
• 52-Week Range: $16.00 to $17.54
• Volume: N/A
• Average Volume: 240 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Santhera Pharmaceuticals Stock Analysis - MarketRank™

Santhera Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Santhera Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Santhera Pharmaceuticals is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Santhera Pharmaceuticals is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 52, which indicates bearish sentiment.

Change versus previous month

Short interest in Santhera Pharmaceuticals has recently increased by 168.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Santhera Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Santhera Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 52, which indicates bearish sentiment.

Change versus previous month

Short interest in Santhera Pharmaceuticals has recently increased by 168.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

Santhera Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Santhera Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Santhera Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 8.23% of the stock of Santhera Pharmaceuticals is held by institutions.

SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed this year?

Santhera Pharmaceuticals' stock was trading at $9.42 at the beginning of the year. Since then, SPHDF stock has increased by 86.2% and is now trading at $17.5367.
View the best growth stocks for 2025 here.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A